Connect with us

Technology

ADC Therapeutics Announces New Employee Inducement Grant

Published

on

LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company’s common shares to a new employee on November 2, 2026. (“Grant”).

The Grant was offered as material inducement to the employee’s employment. The Grant was approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grant was made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08.

The Company is issuing this press release pursuant to Rule 303A.08. The Grant shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.

About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).

ADC Therapeutics’ CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.

Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, or “appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: whether Tanabe’s marketing authorization application filed with Japan’s Ministry of Health for ZYNLONTA will be accepted, the timing and potential approval of the marketing authorization application for ZYNLONTA in Japan, the timing and payment of future regulatory and commercial milestones related to Japan, Nippon Shinyaku ability to successfully commercialize ZYNLONTA in Japan and the amount of future revenue in Japan and related payments to ADCT; the adequacy of the LOTIS-5 clinical trial data to support full regulatory approval and our ability to maintain accelerated approval in the United States and foreign jurisdictions for our product; our ability to identify and execute on potential regulatory and compendia pathways; the timing, content and outcome of meetings with and feedback or other communications provided by regulatory authorities including U.S. FDA including our ability to adequately address the serious concerns related to the LOTIS-5 trial results raised by the FDA at the recent pre-sBLA submission meeting; the timing, submission and outcome of an sBLA related to LOTIS-5 and potential approval; the actual and perceived benefit-risk profile for ZYNLONTA as studied in the LOTIS-5 trial; the assessment of the data from LOTIS-5 study, including additional analyses of outcomes observed for safety, efficacy and within key geographic regions and across certain patient sub-populations; the path for full regulatory approval for ZYNLONTA in the United States and foreign jurisdictions and into earlier lines of therapy; whether future LOTIS-7 results will be consistent with or different from the prior disclosure, the timing, results and publication of the full LOTIS-7 trial data and potential compendia inclusion; future regulatory strategy for a Phase 3 trial for the combination of ZYNLONTA plus glofitamab; our expected revenue growth in 2027 and the Company’s ability to sustain or grow ZYNLONTA® revenue in the future; our expected cash runway into 2029; changes in our regulatory and commercial strategy; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain or maintain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company’s clinical trials; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company’s products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company’s indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company’s activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities; uncertainties related to a potential change in domicile from Switzerland to Delaware, including the outcome of tax analyses associated with such redomiciliation, the receipt of requisite shareholder approval, and the ability to complete the redomiciliation on the anticipated terms and timeline, if at all; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and in the Company’s other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-announces-new-employee-inducement-grant-302925153.html

SOURCE ADC Therapeutics SA

Continue Reading

Technology

FatakSecure Partners with Zurich Kotak General Insurance to Expand Access to Digital Insurance Solutions

Published

on

By

MUMBAI, India, Nov. 12, 2026 /PRNewswire/ — FatakSecure today announced its partnership with Zurich Kotak General Insurance as a Corporate Agent, marking a strategic collaboration aimed at distributing various insurance solutions through digital channels.

Through this partnership, FatakSecure will leverage its digital platform to make insurance solutions more accessible and convenient for customers, while Zurich Kotak General Insurance will offer innovative insurance solutions and underwriting expertise, as part of the company’s broader strategy of expanding its digital ecosystem and reaching customers through innovative distribution channel. Together, the two organisations aim to strengthen insurance distribution and create a seamless digital experience for customers.

Under the partnership:

FatakSecure will act as a Corporate Agent to distribute Zurich Kotak General Insurance’s affinity and motor insurance solutions through its digital platform.Zurich Kotak General Insurance will provide insurance products and support the development of customer-centric insurance offerings.Both organisations will explore opportunities to expand into retail and embedded insurance and identify synergies that enhance customer reach through digital channels.

Commenting on the partnership, Bikash Chaudhary, CEO, FatakSecure, said: “At FatakSecure, our focus has always been on making financial protection solutions more accessible through a seamless digital experience. Our partnership with Zurich Kotak General Insurance marks an important milestone in strengthening insurance offerings and enabling customers to access insurance solutions with greater ease. We look forward to working together to co-create and deliver customer-centric solutions that address evolving protection needs and create long-term value.”

Mr. Birendra Mohanty, Chief Business Officer, Zurich Kotak General Insurance, added, “At Zurich Kotak, we are constantly working towards making protection solutions accessible wherever customers live, transact and engage digitally. Our association with FatakSecure reflects our commitment to making insurance more accessible and convenient for customers. By combining our risk expertise and product innovation capabilities with FatakSecure’s digital platform, we will be able to deliver superior solutions to customers and support the broader agenda of Insurance for All by 2047.”

About FatakSecure:

FatakSecure is a subsidiary of FatakPay Digital. It is licensed as a Composite Corporate Agent to solicit and sale insurance products. FatakSecure is an Insurtech platform enabling digital businesses to seamlessly embed tailored insurance products into their customer journeys. It works with digital NBFCs, lending platforms, fintechs, e-commerce and quick-commerce companies, and gig-economy and rider platforms to simplify insurance distribution and make relevant protection more accessible. Through robust API integrations, digital dashboards, automated MIS, and seamless financial reconciliation, FatakSecure enables partners to streamline and manage their insurance distribution processes while staying focused on their core business. The company is committed to making insurance simpler, transparent, and accessible through technology.

For more information, visit www.fataksecure.com

About FatakPay:

FatakPay is a Mumbai-based fintech platform focused on enabling instant, accessible financial solutions for underserved and emerging India. Through its suite of offerings, including instant loans, insurance, investments, and credit improvement tools, FatakPay aims to simplify and expand access to formal finance. Operating through its subsidiaries, FDPL Finance Pvt. Ltd. (an NBFC registered with the Reserve Bank of India) and FatakSecure (an insurance platform aligned with Insurance Regulatory and Development Authority of India guidelines), the company offers products ranging from instant loans of up to ₹20,000 and personal loans of up to ₹5 lakh, to affordable insurance solutions. Its ecosystem also includes credit-building tools like FatakUdaan, along with digital investment options such as gold and silver. Founded by Ajit Kumar and Abhishek Gandhi (co-founders of RupeeCircle), along with Amit Lodha and Amit Goyal, FatakPay is committed to building a financially resilient India by empowering users with simple, transparent, and reliable financial solutions.

About Zurich Kotak General Insurance:

About Zurich Kotak General Insurance: Zurich Kotak General Insurance Company (India) Limited ((Zurich Kotak General Insurance) is a 70:30 joint venture between Zurich Insurance Group and Kotak Mahindra Bank. The company adopted its new name in August 2024, following Zurich Insurance Group’s acquisition of a 70% stake in Kotak Mahindra General Insurance Company Limited. Originally established in 2015, Zurich Kotak has evolved into one of the youngest and fastest-growing non-life insurance firms in India. The company offers a comprehensive suite of non-life insurance products in Retail and Commercial segments designed to meet the evolving needs of individuals, families, and businesses. Backed by the global legacy of Zurich and the trusted brand of Kotak, the company is committed to building a modern, technology-driven insurance franchise that delivers reliable protection and long-term value, which supports India’s growing insurance penetration and financial resilience.

 

View original content:https://www.prnewswire.com/in/news-releases/fataksecure-partners-with-zurich-kotak-general-insurance-to-expand-access-to-digital-insurance-solutions-302937419.html

Continue Reading

Technology

Desay SV Opens Smart Manufacturing Facility in Linares, Spain, Strengthening Its European Presence

Published

on

By

LINARES, Spain, Nov. 12, 2026 /PRNewswire/ — Desay SV today officially inaugurated its new smart manufacturing facility in Linares, Spain, marking another important step in putting its “In Europe, with Europe, for All” commitment into practice. The facility strengthens the company’s local manufacturing and customer-support capabilities and enables closer collaboration with automotive customers across Europe.

Held at Santana Tech Park, the opening ceremony and press conference brought together Desay SV’s senior leadership, representatives of the Spanish central and regional governments, automotive OEM customers, and industry stakeholders. Among the distinguished guests was Núria Aymerich Rocavert, Special Commissioner for Industrial Competitiveness and Small and Medium-sized Enterprises (SMEs) at the Ministry of Industry and Tourism of the Government of Spain.

Building a Localized Manufacturing Hub in Europe

With a total built-up area of approximately 20,000 square metres, the Linares facility serves as a key regional hub for Desay SV, integrating localized manufacturing, engineering, and customer support in Europe. Upon completion of its planned phases, the facility will have a maximum designed annual production capacity of 2.8 million units, providing the flexibility to respond to evolving OEM demand.

The site will cover the production of a range of automotive products, including automotive displays and smart cockpit domain controllers, supporting the evolving needs of European automakers as vehicles become increasingly connected, intelligent, and software-defined. Mass production is expected to begin in the first quarter of 2027.

Strengthening Industrial Cooperation with Spain

Desay SV’s investment in Linares reflects the company’s confidence in Spain’s automotive industrial base and the region’s potential as a strategic location for advanced manufacturing. The project is expected to contribute to local industrial capabilities, supply-chain resilience, and skilled employment. 

“Spain continues to strengthen its position as a leading European hub for automotive excellence and technological innovation. Desay SV’s investment in Linares reflects the strength of Spain’s industrial ecosystem and contributes to our shared ambition to advance sustainable mobility and strengthen the competitiveness of the European automotive industry.”

— Núria Aymerich Rocavert, Special Commissioner for Industrial Competitiveness and SMEs at Spain’s Ministry of Industry and Tourism.

“Desay SV’s investment in Linares is a transformative milestone for Andalusia’s industrial future. Driven by our 22% surge in regional industrial output, we are proud to welcome a world-class automotive technology leader to our ecosystem. When an industry pioneer like Desay SV invests here, they come to stay.”

— Jorge Paradela Gutiérrez, Regional Minister of Industry, Energy and Mines of the Junta de Andalucía

Supporting European Automakers with Local Programs

Desay SV Spain S.L. has received formal project nominations from two international automotive manufacturers and is continuing commercial discussions with several other European automakers. These developments underscore the company’s growing engagement with the European automotive market and its commitment to building long-term customer relationships through local presence and support.

“We are proud to be part of Linares’ industrial revival and to contribute to a new chapter in the city’s development. The support and collaboration of the local, regional and national authorities have been instrumental in bringing this project to life. Building on this strong foundation, we look forward to creating new opportunities for local talent, strengthening the regional automotive ecosystem and growing together with the community for years to come.”

 — Ling Jianhui, Executive Vice President and Chief Operating Officer of Desay SV

“The inauguration of our Linares facility represents another important step in putting our ‘In Europe, with Europe, for All’ commitment into practice. By combining Desay SV’s technological expertise with Spain’s strong automotive industrial base, we are establishing a resilient local manufacturing hub that enables us to build closer relationships with European partners and provide faster, more flexible, and tailored services to meet their evolving mobility needs.”

—Yang Yong, Executive Vice President of Desay SV and General Manager of Desay SV Europe

A Growing International Business

Desay SV continues to expand its international business. In the first nine months of 2026, the company recorded revenue of approximately RMB 24.4 billion, representing year-on-year growth of 9.3%. International sales reached approximately RMB 1.6 billion in the first half of 2026, up 55.7% year on year. The company’s European headquarters is located in Weimar, Germany, and its European operations extend across Germany, France, Spain, Sweden, and the Czech Republic. Through this regional network and its Linares manufacturing base, Desay SV aims to respond more effectively to customer requirements and support the transformation of the European automotive industry.

Creating Opportunities for Local Talent

The Linares project is expected to create up to 500 direct jobs by 2030 across manufacturing, engineering, quality, logistics, and management. Desay SV also plans to work with local educational institutions, including the University of Jaén and I.E.S. Himilce, to support talent development and build pathways between education and the automotive industry.

About Desay SV

Desay SV is a mobility technology company with operations spanning 26 locations worldwide. With 40 years of experience, the company focuses on Intelligent Cabin, Intelligent Driving, and Connected Services, supported by capabilities in research and development, design, quality management, and intelligent manufacturing. Its global automotive customers include Chery, Geely, Li Auto, Renault, SAIC, Stellantis, Toyota, Volkswagen, and Volvo. Desay SV ranked 54th in the Automotive News 2026 Top 100 Global Automotive Suppliers. Learn more at www.desaysv.com. 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/desay-sv-opens-smart-manufacturing-facility-in-linares-spain-strengthening-its-european-presence-302937070.html

Continue Reading

Technology

AtkinsRéalis and Türkiye Advance Canada’s Global Nuclear Ambitions Through Stronger Nuclear Technology Cooperation

Published

on

By

Memorandum Of Agreement (MOA) supports Government of Canada’s ambition to expand the global reach of its CANDU® nuclear technology, while supporting Türkiye’s economic and energy goalsFeasibility study will evaluate technical, environmental, infrastructure and economic considerations associated with future nuclear development in TürkiyeProgram establishes a pathway from feasibility through to Front-End Engineering Design (FEED) activities to support future investment decisions

MONTREAL, Nov. 12, 2026 /CNW/ — AtkinsRéalis Group Inc. (TSX: ATRL), a world-class engineering services and nuclear company with offices around the world, today announced that its subsidiary Candu Energy Inc. has taken an important step forward in advancing Canada’s international nuclear ambitions with the signing of a Memorandum of Agreement (MOA) with state-owned Türkiye Nükleer Enerji Anonim Şirketi (TÜNAŞ) at COP31 in Antalya, Türkiye.

“This milestone reflects the federal government’s ambitions to strengthen international partnerships and the global reach of Canadian nuclear expertise, with CANDU nuclear technology at the centre of that strategy,” said Ian L. Edwards, President and Chief Executive Officer, AtkinsRéalis. “We are partnering with Türkiye to support its efforts to achieve its climate commitments and economic and energy security goals with low-carbon, baseload power, while expanding opportunities for Canada’s nuclear sector.”

AtkinsRéalis will undertake a comprehensive feasibility study and Front-End Engineering Design (FEED) for the expansion of Türkiye’s nuclear program. For a potential multi-unit deployment, the study will evaluate the site’s characteristics, infrastructure requirements, environmental considerations and broader project development needs. It will also examine how a future nuclear program could be delivered in Türkiye, including opportunities to develop local supply chains, strengthen domestic nuclear expertise and maximize long-term economic value. The study is expected to be completed before the end of 2027. It will support future planning activities and investment decisions associated with nuclear development opportunities at the site.

Released earlier this year, Canada’s Nuclear Energy Strategy identified international partnerships, exports and market diversification as key priorities for strengthening Canada’s position as a global nuclear leader. The Government of Canada has committed to working with provincial, utility and industry partners to maintain the commercial viability and competitiveness of CANDU technology. Agreements such as this put that commitment into action, with government and industry working together to expand international opportunities for CANDU and bring Canadian nuclear technology and expertise to global markets.

“Countries are looking for reliable ways to strengthen energy security, resilience and meet rising electricity demand, and there is broad consensus that nuclear is an essential part of the solution,” said Joe St. Julian, President, Nuclear, AtkinsRéalis. “From Canada and the United States to Central Europe and the ASEAN region, governments are looking for proven technologies and experienced partners that can help turn nuclear ambitions into reality. Türkiye is an important part of that growth story for AtkinsRéalis.”

Developed in Canada, CANDU is a heavy-water reactor technology with some of the highest capacity factors of all reactors in the world. It is built for today’s world, offering a combination of energy security, fuel flexibility, strong local supply chain opportunities and reliable, large-scale, low-carbon power. These attributes resonate with countries around the world as they seek to build resilient energy systems in a changing geopolitical environment. There are currently 34 CANDU nuclear reactors built on four continents.

About AtkinsRéalis   

Created by the integration of long-standing organizations dating back to 1911, AtkinsRéalis is a world-class engineering services and nuclear company dedicated to engineering a better future for our planet and its people. We create sustainable solutions that connect people, data and technology to transform the world’s infrastructure and energy systems. We deploy global capabilities locally to our clients and deliver unique end-to-end services across the whole life cycle of an asset including consulting, advisory & environmental services, intelligent networks & cybersecurity, design & engineering, procurement, project & construction management, operations & maintenance, decommissioning and capital advisory services. The breadth and depth of our capabilities are delivered to clients in strategic sectors such as Engineering Services and Nuclear, as steward of CANDU® nuclear technology. News and information are available at www.atkinsrealis.com or follow us on LinkedIn. 

About AtkinsRéalis’ Nuclear Business 

AtkinsRéalis has over 70 years of global nuclear expertise, delivering nuclear technology products and full-service solutions to nuclear utilities around the world. AtkinsRéalis is the steward of CANDU® nuclear technology, operating on four continents, and provides advisory and engineering services to other nuclear developers. With an innovative technology portfolio, including access to over 500 patented solutions, AtkinsRéalis solves technically complex challenges across the whole nuclear lifecycle from design and new build through asset management and from life extension and late life management through decommissioning and waste management. AtkinsRéalis operates and manages government nuclear research sites, transforming ageing infrastructure and safely managing legacy nuclear waste. AtkinsRéalis’ CANDU technology also allows for the co-production of medical radioisotopes for cancer detection and treatment. The company also supports cancer treatment through its partnership with TerraPower to extract isotopes from legacy nuclear material. Learn more on our Nuclear market page.  

Forward-Looking Statements

References in this press release to the “Company”, “AtkinsRéalis”, “we”, “us” and “our” mean, as the context may require, AtkinsRéalis Group Inc. or all or some of its subsidiaries or joint arrangements or associates. Statements made in this press release that describe the Company’s expectations or strategies constitute “forward-looking statements”, which can be identified by the use of the conditional or forward-looking terminology such as “aims”, “anticipates”, “assumes”, “believes”, “cost savings”, “estimates”, “expects”, “forecasts”, “goal”, “intends”, “likely”, “may”, “objective”, “outlook”, “plans”, “projects”, “should”, “synergies”, “target”, “vision”, “will” , or other variations thereon. Forward-looking statements also include any other statements that do not refer to historical facts. The Company cautions that, by their nature, forward-looking statements involve risks and uncertainties, and that its actual actions or results could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements are presented for the purpose of assisting investors and others in understanding certain key elements of the Company’s current objectives, strategic priorities, expectations and plans, and in obtaining a better understanding of the Company’s business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Forward-looking statements made in this press release are based on a number of assumptions believed by the Company to be reasonable as at the date hereof. The assumptions are set out throughout the Company’s 2025 annual management disclosure & analysis (“2025 MD&A”) (particularly in the sections entitled “Critical Accounting Judgments and Key Sources of Estimation Uncertainty” and “How We Analyze and Report our Results”) filed with the securities regulatory authorities in Canada, available on SEDAR+ at www.sedarplus.com and on the Company’s website at www.atkinsrealis.com under the “Investors” section. If these assumptions are inaccurate, the Company’s actual results could differ materially from those expressed or implied in such forward-looking statements. In addition, important risk factors could cause the Company’s assumptions and estimates to be inaccurate and actual results or events to differ materially from those expressed in or implied by these forward-looking statements. Those risks are identified in the 2025 MD&A (particularly in the section entitled “Risk and Uncertainties”), as may be updated from time to time in the Company’s interim quarterly MD&A, are not exhaustive. The forward-looking statements herein reflect the Company’s expectations as at the date of this press release and are subject to change after this date. The Company does not undertake to update publicly or to revise any such forward-looking statements whether as a result of new information, future events or otherwise, unless required by applicable legislation or regulation. The forward-looking information and statements contained herein are expressly qualified in their entirety by this cautionary statement.

SOURCE AtkinsRéalis

Continue Reading

Trending